• In early February 2026, Kaplan Fox & Kilsheimer LLP began investigating potential securities violations at Corcept Therapeutics after the FDA issued a Complete Response Letter concluding it could not reach a favorable benefit‑risk assessment for relacorilant without more evidence of effectiveness.
• This setback for a key pipeline candidate raises fresh questions about Corcept’s efforts to reduce dependence on its existing product base and diversify future revenue streams.
• Next, we’ll examine how the FDA’s request for additional relacorilant efficacy data may reshape Corcept’s investment narrative and risk profile.

The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Corcept Therapeutics Investment Narrative Recap

To own Corcept Therapeutics today, you have to believe the company can manage its reliance on Korlym while successfully converting its pipeline into approved, revenue generating therapies. The FDA’s recent Complete Response Letter for relacorilant in hypercortisolism directly affects that story, since it delays a key diversification driver and amplifies the near term risk that Korlym erosion and generic pressure remain the dominant forces in the business.

Against this setback, the recent positive Phase 3 ROSELLA results for relacorilant in platinum resistant ovarian cancer now look even more important. If regulators ultimately clear this indication, it could partially offset the delay in hypercortisolism and support Corcept’s effort to broaden its revenue base beyond Korlym, though the timing and final label remain key open questions.

Yet beneath the headline, investors should also be aware that...

Corcept Therapeutics' narrative projects $2.0 billion revenue and $743.0 million earnings by 2028. This requires 40.7% yearly revenue growth and about a $611 million earnings increase from $132.0 million today.

Uncover how Corcept Therapeutics' forecasts yield a $94.20 fair value, a 130% upside to its current price.

Exploring Other Perspectives

Before this setback, the most pessimistic analysts still projected revenue reaching about US$1.8 billion and earnings near US$558.7 million, but the new FDA pushback and the risk that oncology data fail to support broad cortisol use in solid tumors may lead some of those already cautious voices to reassess their assumptions.

Explore 11 other fair value estimates on Corcept Therapeutics - why the stock might be worth over 8x more than the current price!

Build Your Own Corcept Therapeutics Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Corcept Therapeutics research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Corcept Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Corcept Therapeutics' overall financial health at a glance.

Curious About Other Options?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• AI is about to change healthcare. These 27 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The latest GPUs need a type of rare earth metal called Terbium and there are only 31 companies in the world exploring or producing it. Find the list for free.
• Capitalize on the AI infrastructure supercycle with our selection of the 33 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.